Mandate

Vinge advises Doro in connection with the acquisition of IVS

May 15, 2013

Vinge has advised Doro in connection with the acquisition of the German distributor IVS Industrievertretung Schweiger GmbH (“IVS”). The acquisition price for IVS, including the maximum additional purchase price in 2014 and 2015, amounts to EUR 17.6 million on a cash and debt free basis. The acquisition is financed through a combination of existing cash and bank loans and Doro also has an option to finance part of the acquisition with Doro shares.

Doro’s products and solutions are available in more than 30 countries spanning five continents and the product range includes mobile phones, apps and software, fixed telephony, telecare and solutions within mHealth. Doro’s turnover in 2012 was SEK 837.5 million and the company’s shares are listed on OMX Nasdaq Stockholm, Nordic List, Small-cap.

Vinge primarily advised Doro on the capital markets and corporate law issues pertaining to the acquisition. Vinge’s team consisted of responsible partner Johan Winnerblad together with associates Charlotte Levin, Matthias Pannier, Dain Nevonen and Christian Hybbinette. 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026